

PRVPATENT- OCH REGISTRERINGSVERKET
Patentavdelningen**Intyg
Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0301305-9
Patent application number

(86) Ingivningsdatum 2003-05-05
Date of filing


Stockholm, 2004-03-11

För Patent- och registreringsverket
For the Patent- and Registration Office

Hjördis Segerlund
Hjördis Segerlund

Avgift
Fee 170:-

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



BEST AVAILABLE COPY

**PATENT- OCH
REGISTRERINGSVERKET
SWEDEN**

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

FIELD OF THE INVENTION

The present invention relates to new compounds, to pharmaceutical formulations
5 containing said compounds and to the use of said compounds in therapy. The present
invention further relates to processes for the preparation of said compounds and to new
intermediates used in the preparation thereof.

10 BACKGROUND OF THE INVENTION

Pain sensation in mammals is due to the activation of the peripheral terminals of a
specialized population of sensory neurons known as nociceptors. Capsaicin, the active
ingredient in hot peppers, produces sustained activation of nociceptors and also produces a
15 dose-dependent pain sensation in humans. Cloning of the vanilloid receptor 1 (VR1 or
TRPV1) demonstrated that VR1 is the molecular target for capsaicin and its analogues.
(Caterina, M.J., Schumacher, M.A., et al. Nature 1997 v.389 p 816-824). Functional studies
using VR1 indicate that it is also activated by noxious heat and that the threshold for
activation can be lowered below normal body temperature by a reduction of the
20 extracellular pH value (acidification) and by other inflammatory mediators Tominaga, M.,
Caterina, M.J. et al. Neuron 1998 v.21, p.531-543). Expression of VR1 is also regulated
after peripheral nerve damage of the type that leads to neuropathic pain. These properties
of VR1 make it a highly relevant target for pain and for diseases involving inflammation.
Agonists of the VR1 receptor can act as analgesics, but the usefulness of agonists, such as
25 capsaicin and its analogues, is limited by their pungency, neurotoxicity and induction of
hypothermia. Pain-evoking stimuli activate the VR1 receptor and agents that block the
activity of VR1 have also shown analgesic activity in animals.

Compounds with VR1 blocker activity are believed to be of potential use for the treatment
or prophylaxis of disorders such as pain, especially that of inflammatory or traumatic
30 origin such as arthritis, fibromyalgia, low back pain and post-operative pain. (Walker et al
J Pharmacol Exp Ther. 2003 Jan; 304(1):56-62), or visceral pains such as chronic pelvic
pain, cystitis, irritable bowel syndrome (IBS), pancreatitis and the like, and also


PRUN3-05-05

neuropathic pain such as sciatica, diabetic neuropathy and HIV neuropathy, and the like (Walker et al *ibid*, Rashid et al J Pharmacol Exp Ther. 2003 Mar;304(3):940-8). These compounds are also believed to be potentially useful for inflammatory disorders like asthma, cough, inflammatory bowel disease (IBD) (Hwang and Oh Curr Opin Pharmacol 2002 Jun; 2(3):235-42). Compounds with VR1 blocker activity are also useful for itch and skin diseases like psoriasis and for gastro-esophageal reflux disease (GERD), emesis, urinary incontinence and hyperactive bladder (Yiangou et al BJU Int 2001 Jun; 87(9): 774-9, Szallasi Am J Clin Pathol 2002 118: 110-21). VR1 inhibitors are also of potential use for the treatment or prophylaxis of the effects of exposure to VR1 activators like capsaicin or tear gas, acids or heat (Szallasi *ibid*).

DETAILED DESCRIPTION OF THE INVENTION

The object of the present invention is to provide compounds exhibiting an activity at the vanilloid receptor 1 (VR1).

The present invention provides a compound of formula I



(I)

wherein:

ring P is C₆₋₁₀aryl, C₃₋₇cycloalkyl, C₅₋₆heteroaryl, whereby ring P may be fused with phenyl, C₃₋₆heteroaryl, C₃₋₇cycloalkyl or C₃₋₇heterocycloalkyl;

R¹ is H, NO₂, NH₂, halo, N(C₁₋₆alkyl)₂, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆haloalkylO, phenylC₀₋₆alkyl, C₅₋₆heteroarylC₀₋₆alkyl, C₃₋₇cycloalkylC₀₋₆alkyl, C₃₋₇heterocycloalkylC₀₋₆alkyl, C₁₋₆alkylOC₀₋₆alkyl, C₁₋₆alkylSC₀₋₆alkyl or

PRU 03 05 05

3

$C_{1-6}alkylNC_{0-6}alkyl$;

n is 1, 2, 3 or 4;

M is $C_{0-4}alkyl$, $C_{1-6}alkylNC_{0-6}alkyl$, N or O ;

R^2 is H or $C_{0-4}alkyl$;

5 R^3 is H , $C_{1-6}alkyl$, halo, $C_{1-6}haloalkyl$, $C_{1-6}haloalkylO$, $C_{1-6}alkylOC_{1-6}alkyl$, $R^5OC_{1-6}alkyl$, R^5CO , CO_2R^5 , $CONR^5R^6$ or NR^5R^6 ;

X is N , O or S ;

R^4 is H or $C_{0-4}alkyl$;

R^5 and R^6 are independently selected from H and $C_{1-6}alkyl$;

10 and wherein any alkyl, alkylOalkyl, haloalkyl, haloalkylO, phenyl, heteroaryl, cycloalkyl or heterocycloalkyl group may be substituted with one or more A ; and

A is OH , NO_2 , NH_2 , CO , $O(CO)$ or halo;

or salts, solvates or solvated salts thereof.

15 One embodiment of the invention relates to the compound of formula I wherein ring P is $C_{6-10}aryl$ or $C_{5-6}heteroaryl$, whereby ring P may be fused with phenyl or

$C_{3-7}heterocycloalkyl$;

R^1 is H , NO_2 , NH_2 , halo, $N(C_{1-6}alkyl)_2$, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{1-6}haloalkyl$, $OC_{1-6}haloalkyl$, phenyl $C_{0-6}alkyl$, $C_{0-6}alkylOC_{1-6}alkyl$ or $C_{0-6}alkylSC_{1-6}alkyl$;

20 n is 1, 2 or 3;

M is $C_{0-4}alkyl$, $C_{0-4}alkylNH$ or N ;

R^2 is H or $C_{0-4}alkyl$;

R^3 is $C_{1-6}alkyl$, $R^5OC_{1-6}alkyl$, R^5CO or CO_2R^5 ;

R^4 is H or $C_{1-4}alkyl$;

25 R^5 is H and $C_{1-6}alkyl$;

X is N , O or S ; and

A is OH , NO_2 , NH_2 or halo.

30 Another embodiment of the invention relates to the compound of formula I wherein ring P is phenyl and R^1 is H , NO_2 , NH_2 , halo, $N(C_{1-6}alkyl)_2$, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{1-6}haloalkyl$, $C_{1-6}haloalkylO$, phenyl $C_{0-6}alkyl$, $C_{5-6}heteroarylC_{0-6}alkyl$, $C_{3-7}cycloalkylC_{0-6}alkyl$, $C_{3-7}heterocycloalkylC_{0-6}alkyl$, $C_{1-6}alkylOC_{0-6}alkyl$,

PRV03-05-05

$C_{1-6}alkylSC_{0-6}alkyl$ or $C_{1-6}alkylNC_{0-6}alkyl$.

Ring P may be substituted with 0, 1, 2, 3, or 4 substituents R^1 wherein the number of substituents is designated by the term n. The substituent R^1 is selected from the group consisting of H, NO_2 , NH_2 , halo, $N(C_{1-6}alkyl)_2$, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{1-6}haloalkyl$, $C_{1-6}haloalkylO$, $phenylC_{0-6}alkyl$, $C_{5-6}heteroarylC_{0-6}alkyl$, $C_{3-7}cycloalkylC_{0-6}alkyl$, $C_{3-7}heterocycloalkylC_{0-6}alkyl$, $C_{1-6}alkylOC_{0-6}alkyl$, $C_{1-6}alkylSC_{0-6}alkyl$ and $C_{1-6}alkylNC_{0-6}alkyl$.

In one embodiment of the invention R^1 is elected from the group consisting of H, NO_2 , NH_2 , halo, $N(C_{1-6}alkyl)_2$, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{1-6}haloalkyl$, $OC_{1-6}haloalkyl$, $phenylC_{0-6}alkyl$, $C_{0-6}alkylOC_{1-6}alkyl$ and $C_{0-6}alkylSC_{1-6}alkyl$ and n is 0, 1, or 2.

Ring P may be substituted by R^1 on a nitrogen or carbon atom in ring P. Further, one atom on ring P may be substituted by two substituents R^1 .

M is selected from the group consisting of $C_{0-4}alkyl$, $C_{0-4}alkylNH$ and N. In one embodiment of the invention M is a direct bond between C=O and ring P. In another embodiment of the invention M is N or O. In yet another embodiment of the invention M is $C_{1-2}alkyl$ or $C_{1-2}alkylN$.

M may be substituted by substituent R^2 . In one embodiment R^2 is H when M is N or alkyl.

R^3 may be selected from the group consisting of H, $C_{1-6}alkyl$, halo, $C_{1-6}haloalkyl$, $C_{1-6}haloalkylO$, $C_{1-6}alkylOC_{1-6}alkyl$, $R^5OC_{1-6}alkyl$, R^5CO , CO_2R^5 , $CONR^5R^6$ or NR^5R^6 whereby R^5 and R^6 are independently selected from H and $C_{1-6}alkyl$.

One embodiment of the invention relates to the compound of formula I wherein R^3 is hydroxymethyl, formyl, hydroxycarbonyl or methoxycarbonyl.

X may be selected from the group consisting of N, O and S. X may be substituted with R^4 when X is N. One embodiment of the invention relates to compounds of formula I wherein X is S.

Any alkyl, alkylOalkyl, haloalkyl, haloalkylO, phenyl, heteroaryl, cycloalkyl or heterocycloalkyl group present in the substituents of the compounds of formula I may be

substituted with one or more A. One embodiment of the invention relates to compounds of formula I wherein A is selected from the group consisting of OH, NO₂, NH₂, CO, O(CO) and halo.

5 Another embodiment of the invention relates to compounds selected from the group consisting of

- 4-*tert*-Butyl-*N*-(2-formyl-benzothiazol-5-yl)-benzamide,
4-*tert*-Butyl-*N*-(2-hydroxymethyl-benzthiazol-5-yl)-benzamide,
5-(4-*tert*-butylbenzoylamino)benzothiazol-2-ylcarboxylic acid, and
10 4-*tert*-Butyl-*N*-(2-methoxycarbonylbenzthiazol-5-yl)-benzamide,
or salts, solvates or solvated salts thereof.

Listed below are definitions of various terms used in the specification and claims to describe the present invention.

15

For the avoidance of doubt it is to be understood that where in this specification a group is qualified by 'hereinbefore defined', 'defined hereinbefore' or 'defined above' the said group encompasses the first occurring and broadest definition as well as each and all of the other definitions for that group.

20

For the avoidance of doubt it is to be understood that in this specification 'C₁₋₆' means a carbon group having 1, 2, 3, 4, 5 or 6 carbon atoms.

25

In this specification, unless stated otherwise, the term "alkyl" includes both straight and branched chain alkyl groups and may be, but are not limited to methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl or i-hexyl, t-hexyl. The term C₁₋₃ alkyl having 1 to 3 carbon atoms and may be methyl, ethyl, n-propyl, i-propyl or *tert*-butyl.

30

The term 'C₀' means a bond or does not exist. For example when M is C₀alkyl, M is a bond and "arylC₀alkyl" is equivalent with "aryl", "C₂aklylOC₀alkyl" is equivalent with "C₂alkylO".

In this specification, unless stated otherwise, the term "alkenyl" includes both straight and branched chain alkenyl groups. The term " C_{2-6} alkenyl" having 2 to 6 carbon atoms and one or two double bonds, may be, but is not limited to vinyl, allyl, propenyl, butenyl, crotyl, pentenyl, or hexenyl, and a butenyl group may for example be buten-2-yl, buten-3-yl or buten-4-yl.

In this specification, unless stated otherwise, the term "alkynyl" includes both straight and branched chain alkynyl groups. The term " C_{2-6} alkynyl" having 2 to 6 carbon atoms and one or two trippel bonds, may be, but is not limited to etynyl, propargyl, pentynyl or hexynyl and a butynyl group may for example be butyn-3-yl or butyn-4-yl.

In this specification, unless stated otherwise, the term "cycloalkyl" refers to an optionally substituted, saturated cyclic hydrocarbon ring system. The term " C_{3-7} cycloalkyl" may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

The term "heterocycloalkyl" denotes a 3- to 7-membered, non-aromatic, partially or completely saturated hydrocarbon group, which contains one rings and at least one heteroatom. Examples of said heterocycle include, but are not limited to pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, benzofuryl, indolyl, isoindolyl, benzimidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrazolyl, triazolyl, pyrrolidinyl, pyrrolidonyl, piperidiny, piperazinyl, morpholiny, oxazolyl, 2-oxazolidonyl or tetrahydrofuranyl.

In this specification, unless stated otherwise, the term "aryl" refer to an optionally substituted monocyclic or bicyclic hydrocarbon unsaturated aromatic ring system. Examples of "aryl" may be, but are not limited to phenyl and naphthyl.

In this specification, unless stated otherwise, the term "heteroaryl" refer to an optionally substituted monocyclic or bicyclic unsaturated aromatic ring system containing at least one heteroatom selected independently form N, O or S. Examples of "heteroaryl" may be, but are not limited to pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl,

thiazolyl, pyrazolyl, benzofuryl, indolyl, isoindolyl, benzimidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrazolyl, triazolyl and oxazolyl.

In this specification, unless stated otherwise, the term "arylalkyl" and "heteroarylalkyl" refer to a substituent that is attached via the alkyl or group to an aryl group.

In this specification, unless stated otherwise, the term "halo" and "halogen" may be fluoro, iodo, chloro or bromo.

In this specification, unless stated otherwise, the term "haloalkyl" means an alkyl group as defined above, which is substituted with halo as defined above. The term " C_{1-6} haloalkyl" may include, but is not limited to fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl or bromopropyl. The term " C_{1-6} haloalkylO" may include, but is not limited to fluoromethoxy, difluoromethoxy, trifluoromethoxy, fluoroethoxy or difluoroethoxy.

The present invention relates to the compounds of formula I as hereinbefore defined as well as to the salts, solvates or solvated salts thereof. Salts for use in pharmaceutical formulations will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I.

A suitable pharmaceutically acceptable salt of the compounds of the invention is, for example, an acid-addition salt, for example an inorganic or organic acid. In addition, a suitable pharmaceutically acceptable salt of the compounds of the invention is an alkali metal salt, an alkaline earth metal salt or a salt with an organic base.

Other pharmaceutically acceptable salts and methods of preparing these salts may be found in, for example, Remington's Pharmaceutical Sciences (18th Edition, Mack Publishing Co.).

Some compounds of formula I may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomeric and geometric isomers.

The invention also relates to any and all tautomeric forms of the compounds of formula I.


Methods of Preparation

- 5 Another aspect of the present invention provides processes for preparing compounds of formula I, or salts, solvates or solvated salts thereof.
- Throughout the following description of such processes it is to be understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from, the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are described, for example, in
- 10 "Protective Groups in Organic Synthesis", T.W. Green, P.G.M. Wuts, Wiley-Interscience, New York, (1999). References and descriptions of other suitable reactions are described in textbooks of organic chemistry, for example, "Advanced Organic Chemistry", March, 4th ed. McGraw Hill (1992) or, "Organic Synthesis", Smith, McGraw Hill, (1994). For representative examples of heterocyclic chemistry see for example "Heterocyclic Chemistry", J. A. Joule, K. Mills, G. F. Smith, 3rd ed. Chapman and Hall (1995), p. 189-224 and "Heterocyclic Chemistry", T. L. Gilchrist, 2nd ed. Longman Scientific and Technical (1992), p. 248-282.
- 15 The term "room temperature" and "ambient temperature" shall mean, unless otherwise specified, a temperature between 16 and 25 °C.
- 20

One embodiment of the invention relates to processes for the preparation of the compound of formula I according to Methods A and B, wherein R¹ to R⁴, unless otherwise specified, are defined as in formula I, comprising;

25

Method A




whereby the amide of formula I is obtained from the amine of formula II and an appropriate acyl chloride of formula III.

This reaction may be performed in any manner known to the skilled person in the art. Suitable solvents to be used for this reaction may be halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane or aromatic and heteroaromatic compounds such as benzene, toluene, xylene, pyridine and lutidine or ethers such as ethyl ether, tetrahydrofuran and dioxan or any mixtures thereof. Catalysts such as heteroaromatic bases like pyridine and lutidine or tertiary amines like triethylamine, *N*-methylmorpholine and ethyl diisopropylamine may be used as well. The temperature may be between -40 and 40°C and the reaction time may be between 0.5 and 30 h.

Or,


Method B



whereby the amide of formula I is obtained from the amine of formula II and an appropriate carboxylic acid of formula IV in the presence of a coupling agent like for example 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride.

This reaction may be performed in any manner known to the skilled person in the art. Suitable solvents to be used for this reaction may be tertiary amides such as dimethylformamide and dimethylacetamide, halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane or aromatic and heteroaromatic compounds such as benzene, toluene, xylene, pyridine and lutidine or ethers such as ethyl ether, tetrahydrofuran and dioxan or any mixtures thereof. Catalysts such as heteroaromatic bases like pyridine and lutidine or tertiary amines like triethylamine, *N*-methylmorpholine and ethyl diisopropylamine may be used as well. The temperature may be between 10 and 60°C and the reaction time may be between 3 and 30 h.

Or,

Method C

whereby the aldehyde of formula V is obtained from 5-amino-2-methylbenzothiazole by treatment with an appropriate oxidative reagent for example, magnesium dioxide, chromium trioxide or selenium dioxide whereafter the intermediate of formula V is converted to the compounds of formula Ia, Ib, Ic or Id according to Method A or Method B.

The first reaction may be performed in any manner known to the skilled person in the art. Suitable solvents to be used for this reaction may be ketones such as acetone and butan-2-one, or halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane or any mixtures thereof. The temperature may be between 0 and 80°C and the reaction time may be between 3 and 50 h.

The intermediate of formula V may be converted to target compounds of formula Ia, Ib, Ic or Id, in any manner known to the skilled person in the art. Thus, a reaction of the compound of formula V with an appropriate acid (method A) or acyl chloride (method B) gives a compound of formula Ia. The latter may be converted by reduction with sodium borohydride to an alcohol of formula Ib or by oxidation with sodium chlorite to the carboxylic acid of formula Ic. The mentioned acid may be converted to the corresponding methyl ester of formula Id by treatment with methanol in acidic environment.

A further embodiment of the invention relates to compounds 4-tert-Butyl-N-(2-formylbenzothiazol-5-yl)-benzamide and 5-(4-tert-butylbenzoylamino)benzothiazol-2-ylcarboxylic acid, which may be used as intermediates in the preparation of the compound of formula I.

Pharmaceutical formulation

5 According to one aspect of the present invention there is provided a pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound of formula I, or salts, solvates or solvated salts thereof, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.

10 The composition may be in a form suitable for oral administration, for example as a tablet, pill, syrup, powder, granule or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration e.g. as an ointment, patch or cream or for rectal administration e.g. as a suppository.

15 In general the above compositions may be prepared in a conventional manner using one or more conventional excipients, pharmaceutical acceptable diluents and/or inert carriers.

Suitable daily doses of the compound of formula I in the treatment of a mammal, including man are approximately 0.01 to 250 mg/kg bodyweight at peroral administration and about 0.001 to 250 mg/kg bodyweight at parenteral administration. The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the
20 relevant indication, severity of the illness being treated, the route of administration, the age, weight and sex of the patient and the particular compound being used, and may be determined by a physician.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Medical use

Surprisingly, it has been found that the compounds according to the present invention are useful in therapy. The compounds of formula I, or salts, solvates or solvated salts thereof, as well as their corresponding active metabolites, exhibit a high degree of potency and selectivity for individual vanilloid receptor 1 (VR1) groups. Accordingly, the compounds of the present invention are expected to be useful in the treatment of conditions associated with excitatory activation of vanilloid receptor 1 (VR1).

The compounds may be used to produce an inhibitory effect of VR1 in mammals, including man.

VR1 are highly expressed in the peripheral nervous system and in other tissues.

Thus, it is expected that the compounds of the invention are well suited for the treatment of VR1 mediated disorders. The compounds of formula I are expected to be suited for the treatment of acute and chronic pain and acute and chronic inflammatory pain. The compound may further be suited for the treatment of chronic neuropathic pain.

Examples of such disorder may be selected from the group comprising of arthritis, fibromyalgia, low back pain, post-operative pain, visceral pains like chronic pelvic pain, cystitis, irritable bowel syndrome (IBS), pancreatitis, sciatica, diabetic neuropathy, HIV neuropathy, asthma, cough, inflammatory bowel disease (IBD) and psoriasis.

Further relevant disorders that may be treated using the compounds of formula I may be selected from the group comprising of gastro-esophageal reflux disease (GERD), emesis, urinary incontinence and hyperactive bladder.

The compounds of formula I may also be used as antitoxin to treat (over-) exposure to VR1 activators like capsaicin or tear gas, acids or heat.

The compounds may further be used for treatment of tolerance to VR1 activators.

One embodiment of the invention relates to the use of the compound of formula I in therapy.

Another embodiment of the invention relates to the use of the compound of formula I for treatment of VR1 mediated disorders.

A further embodiment of the invention relates to the use of the compound of formula I for treatment of acute and chronic pain disorders

- 5 Yet another embodiment of the invention relates to the use of the compound of formula I for treatment of acute and chronic inflammatory pain.

Yet a further embodiment of the invention relates to the use of the compound of formula I as hereinbefore defined, for treatment of indications selected from the group consisting of
10 arthritis, fibromyalgia, low back pain, post-operative pain, visceral pains like chronic pelvic pain, cystitis, IBS, pancreatitis, sciatica, diabetic neuropathy, HIV neuropathy, asthma, cough, IBD, psoriasis, gastro-esophageal reflux disease (GERD), emesis, urinary incontinence and hyperactive bladder.

- 15 One embodiment of the invention relates to the use of the compound of formula I as hereinbefore defined, in the manufacture of a medicament for the treatment of VR1 mediated disorders and for the treatment of acute and chronic pain disorders and acute and chronic inflammatory pain and any other disorder mentioned above.

- 20 Another embodiment of the invention relates to a method of treatment of VR1 mediated disorders and acute and chronic pain disorders and acute and chronic inflammatory pain and any other disorder mentioned above, comprising administering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compound of formula I, as hereinbefore defined.

- 25 A further embodiment of the invention relates to a pharmaceutical formulation comprising the compound of formula I, as hereinbefore defined, for use in the treatment of VR1 mediated disorders and for the treatment of acute and chronic pain disorders and acute and chronic inflammatory pain and any other disorder mentioned above.
- 30

PNV507-05

PNV507-05

PNV507-05

PNV507-05

PNV507-05

PNV507-05

PNV507-05

PNV507-05

PNV507-05

Example 47**4-tert-Butyl-N-(2-formyl-benzothiazol-5-yl)-benzamide**

Part A. Manganese dioxide (10 mmol) was added to a solution of 5-amino-2-methylbenzothiazole (2 mmol) in acetone (20 mL). The mixture was refluxed for 24 h.

5 After cooling to ambient temperature, the mixture was filtered and concentrated *in vacuo* to afford crude 5-amino-2-formylbenzothiazole as a yellow oil which was used for the next step without further purification. MS (ESI⁺) *m/z* 179 [M+H]⁺

Part B. 5-amino-2-formylbenzothiazole (0.5 mmol) was dissolved in methylene chloride
10 (10 mL) and treated sequentially with triethylamine (1 mmol) and 4-tert-butylbenzoyl chloride (0.6 mmol). The mixture was stirred at ambient temperature for 12 h, then quenched by addition of about 1 mL of saturated ammonium chloride solution. The mixture was then partitioned between ethyl acetate (15 mL) and water (15 mL). The organic phase was separated, dried over anhydrous sodium sulphate and concentrated *in vacuo*. The oily
15 residue was then purified by preparative HPLC (X-Terra C8 column, 19x 300 mm), using a gradient of A (water 95%, containing NH₄OAc (0.01 M), and 5% acetonitrile) and B (acetonitrile), to give the title compound as a solid MS (ESI⁺) *m/z* 339 [M+H]⁺, ¹H NMR (400 MHz, DMSO-d₆) δ 1.35 (s, 9 H), 7.27 (d, *J*=8.6 Hz, 2 H), 7.60-7.73 (m, 2H), 7.73 (d, *J*=8.6 Hz, 1 H), 7.86 (s, 1 H), 8.13 (s, 1 H), 8.84 (s, 1H).

20

Example 48**4-tert-Butyl-N-(2-hydroxymethyl-benzthiazol-5-yl)-benzamide**

Sodium borohydride (0.1 mmol) was added to a solution of 4-tert-butyl-N-(2-formyl-benzothiazol-5-yl)-benzamide (0.1 mmol) in methanol (2 mL). The mixture was stirred at
25 ambient temperature for 1 h, then quenched by addition of about 0.5 mL of water. The mixture was then partitioned between ethyl acetate (3 mL) and water (3 mL); the organic phase was separated, dried over anhydrous sodium sulphate and concentrated *in vacuo*. The oily residue was then purified by preparative HPLC (X-Terra C8 column, 19x 300 mm), using a gradient of A (water 95%, containing NH₄OAc (0.01 M), and 5%
30 acetonitrile) and B (acetonitrile), to give the title compound as a solid. MS (ESI⁺) *m/z* 341 [M+H]⁺, ¹H NMR (400 MHz, DMSO-d₆) δ 1.30 (s, 9 H), 3.12 (s, 1H), 4.42 (s, 2H) 7.22 (d, *J*=8.6 Hz, 2 H), 7.62-7.76 (m, 2H), 7.83 (d, *J*=8.6 Hz, 1 H), 7.96 (s, 1 H), 8.25 (s, 1 H).

Example 49***5-(4-tert-butylbenzoylamino)benzothiazol-2-ylcarboxylic acid***

A solution of 4-tert-butyl-N-(2-formyl-benzothiazol-5-yl)-benzamide (0.1 mmol) in THF (2 mL) was treated sequentially with a solution of sulfamic acid (0.2 mmol) in water (0.5 mL) and a solution of sodium chlorite (0.15 eq) in water (0.5 mL). The mixture was stirred at ambient temperature for 1 h, then partitioned between ethyl acetate (5 mL) and water (5 mL). The organic phase was separated, the water phase was extracted 3 times with ethyl acetate. Combined organic phase was dried over anhydrous sodium sulphate and concentrated *in vacuo*. The crude material was purified by preparative HPLC (X-Terra C8 column, 19x 300 mm), using a gradient of A (water 95%, containing NH₄OAc (0.01 M), and 5% acetonitrile) and B (acetonitrile), to give the title compound. MS (ESI⁺) *m/z* 355 [M+H]⁺

Example 50***4-tert-Butyl-N-(2-methoxycarbonylbenzthiazol-5-yl)-benzamide***

A solution of 5-(4-tert-butylbenzoylamino)benzothiazol-2-yl carboxylic acid (0.1 mmol) in methanol (3 mL) was treated with one drop of concentrated hydrochloric acid. The mixture was concentrated to dryness *in vacuo*. The oily residue was then purified by preparative HPLC (X-Terra C8 column, 19x 300 mm), using a gradient of A (water 95%, containing NH₄OAc (0.01 M), and 5% acetonitrile) and B (acetonitrile), to give the title compound as a solid. MS (ESI⁺) *m/z* 369 [M+H]⁺, ¹H NMR (400 MHz, DMSO-d₆) δ 1.32 (s, 9 H), 3.65 (s, 1H), 7.25 (d, *J*=8.6 Hz, 2 H), 7.65-7.79 (m, 2H), 7.85 (d, *J*=8.6 Hz, 1 H), 7.91 (s, 1 H), 8.29 (s, 1 H).

Pharmacology

DRGs were dissected out from adult Sprague Dawley rats (100-300 gr), and placed on ice in L15 Leibovitz medium. The ganglia were enzyme treated with Collagenase 80U/ml+ Dispase 34 U/ml dissolved in DMEM +5% serum, overnight at 37 °C. The next day, cells were triturated with fire polished pasteur pipettes, and seeded in the center of 58 mm diameter Nunc cell dishes coated with Poly-D Lysine (1 mg/mL). The DRGs were cultured

in a defined medium without foetal bovine serum, containing Dulbecco's MEM / NUT MIX F-12 (1:1) without L-glutamine but with pyridoxine, 6 mg/mL D(+)-Glucose, 100 µg/mL apo-transferrin, 1 mg/mL BSA, 20 µg/mL insulin, 2 mM L-glutamine, 50 IU/mL Penicillin, 50 µg / mL Streptomycin and 0.01 µg/mL NGF-7S.

5

When the cells had grown for 2 days up to 4 weeks, the experiments were done. Cells were chosen based on size and presence of neurites. Small cells with long processes were used for recording (most likely to be C neurons, with native VR1 receptors).

- 10 The cells were recorded with conventional whole cell voltage clamp patch clamp, using the following solutions (calcium ion free):

The extracellular solution comprised (in mM): NaCl 137, KCl 5, MgCl₂ * H₂O 1.2, HEPES 10, Glucose 10, EGTA 5, Sucrose 50, pH to 7.4 with NaOH.

- 15 The intracellular solution comprised K-gluconate 140, NaCl 3, MgCl₂ * H₂O 1.2, HEPES 10, EGTA 1, pH to 7.2 with KOH. When the cells were penetrated with suction, a puff of capsaicin (500 nM) was used to determine if the cell expressed VR1 receptor. If not, a new cell was chosen. If yes, then the compounds were added in increasing doses before the capsaicin pulse (500 nM), to determine an IC₅₀ value.

20 List of abbreviations

VR1	vanilloid receptor 1
IBS	irritable bowel syndrome
IBD	inflammatory bowel disease
GERD	gastro-esophageal reflux disease
25 DRG	Dorsal Root Ganglion
BSA	Bovine Serum Albumin
HEPES	4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
EGTA	Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid
DMEM	Dulbeccos Modified Eagle's Medium

30


Results

Typical IC_{50} values as measured in the assays described above are 10 μ M or less. In one aspect of the invention the IC_{50} is below 500 nM. In another aspect of the invention the IC_{50} is below 100 nM. In a further aspect of the invention the IC_{50} is below 10 nM.

P7003-75-05

CLAIMS

1. A compound having the formula I



5 wherein:

ring P is C₆₋₁₀aryl, C₃₋₇cycloalkyl, C₅₋₆heteroaryl, whereby ring P may be fused with phenyl, C₅₋₆heteroaryl, C₃₋₇cycloalkyl or C₃₋₇heterocycloalkyl;

R¹ is H, NO₂, NH₂, halo, N(C₁₋₆alkyl)₂, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆haloalkylO, phenylC₀₋₆alkyl, C₅₋₆heteroarylC₀₋₆alkyl, C₃₋₇cycloalkylC₀₋₆alkyl,

10 C₃₋₇heterocycloalkylC₀₋₆alkyl, C₁₋₆alkylOC₀₋₆alkyl, C₁₋₆alkylSC₀₋₆alkyl or C₁₋₆alkylNC₀₋₆alkyl;

n is 1, 2, 3 or 4;

M is C₀₋₄alkyl, C₁₋₆alkylNC₀₋₆alkyl, N or O;

R² is H or C₀₋₄alkyl;

15 R³ is H, C₁₋₆alkyl, halo, C₁₋₆haloalkyl, C₁₋₆haloalkylO, C₁₋₆alkylOC₁₋₆alkyl, R⁵OC₁₋₆alkyl, R⁵CO, CO₂R⁵, CONR⁵R⁶ or NR⁵R⁶;

X is N, O or S;

R⁴ is H or C₀₋₄alkyl;

R⁵ and R⁶ are independently selected from H and C₁₋₆alkyl;

20 and wherein any alkyl, alkylOalkyl, haloalkyl, haloalkylO, phenyl, heteroaryl, cycloalkyl or heterocycloalkyl group may be substituted with one or more A; and

A is OH, NO₂, NH₂, CO, O(CO) or halo;

or salts, solvates or solvated salts thereof.

25 2. The compound according to claim 1 wherein ring P is C₆₋₁₀aryl or C₅₋₆heteroaryl, whereby ring P may be fused with phenyl or C₃₋₇heterocycloalkyl;

R^1 is H, NO_2 , NH_2 , halo, $\text{N}(\text{C}_{1-6}\text{alkyl})_2$, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{1-6}\text{haloalkyl}$, $\text{OC}_{1-6}\text{haloalkyl}$, $\text{phenylC}_{0-6}\text{alkyl}$, $\text{C}_{0-6}\text{alkylOC}_{1-6}\text{alkyl}$ or $\text{C}_{0-6}\text{alkylSC}_{1-6}\text{alkyl}$;

n is 1, 2 or 3;

M is $\text{C}_{0-4}\text{alkyl}$, $\text{C}_{0-4}\text{alkylNH}$ or N ;

5 R^2 is H or $\text{C}_{0-4}\text{alkyl}$;

R^3 is $\text{C}_{1-6}\text{alkyl}$, $\text{R}^5\text{OC}_{1-6}\text{alkyl}$, R^5CO or CO_2R^5 ;

R^4 is H or $\text{C}_{1-4}\text{alkyl}$;

R^5 is H and $\text{C}_{1-6}\text{alkyl}$;

X is N, O or S; and

10 A is OH, NO_2 , NH_2 or halo.


3. The compound according to any one of claims 1 or 2 wherein ring P is phenyl and R^1 is H, NO_2 , NH_2 , halo, $\text{N}(\text{C}_{1-6}\text{alkyl})_2$, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{1-6}\text{haloalkyl}$, $\text{C}_{1-6}\text{haloalkylO}$, $\text{phenylC}_{0-6}\text{alkyl}$, $\text{C}_{5-6}\text{heteroarylC}_{0-6}\text{alkyl}$, $\text{C}_{3-7}\text{cycloalkylC}_{0-6}\text{alkyl}$,
 15 $\text{C}_{3-7}\text{heterocycloalkylC}_{0-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkylOC}_{0-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkylSC}_{0-6}\text{alkyl}$ or $\text{C}_{1-6}\text{alkylNC}_{0-6}\text{alkyl}$.

4. The compound according to any one of claims 1 to 3 wherein R^3 is hydroxymethyl, formyl, hydroxycarbonyl or methoxycarbonyl.

20


5. The compounds selected from the group consisting of
 4-*tert*-Butyl-*N*-(2-formyl-benzothiazol-5-yl)-benzamide,
 4-*tert*-Butyl-*N*-(2-hydroxymethyl-benzthiazol-5-yl)-benzamide,
 5-(4-*tert*-butylbenzoylamino)benzothiazol-2-ylcarboxylic acid, and
 25 4-*tert*-Butyl-*N*-(2-methoxycarbonylbenzthiazol-5-yl)-benzamide,
 or salts, solvates or solvated salts thereof.

6. A processes for the preparation of the compound according to claim 1, wherein R^1 to R^4 , are defined as in claim 1, comprising;

Method A


whereby the amide of formula I is obtained from the amine of formula II and an appropriate acyl chloride of formula III;

or

Method B

whereby the amide of formula I is obtained from the amine of formula II and an appropriate carboxylic acid of formula IV in the presence of a coupling agent,

or,

Method C

whereby the aldehyde of formula V is obtained from 5-amino-2-methylbenzothiazole by treatment with an appropriate oxidative reagent, whereafter the intermediate of formula V is converted to the compounds of formula Ia, Ib, Ic or Id according to Method A or Method B.

7. The compound according to any one of claims 1 to 5, for use in therapy.

8. Use of the compound according to any one of claims 1 to 5, in treatment of VR1 mediated disorders.

9. The use according to claim 8 for treatment of acute and chronic pain disorders.

10. The use according to claim 8 for treatment of acute and chronic inflammatory pain.

11. The use according to claim 8 for treatment of indications selected from the group consisting of arthritis, fibromyalgia, low back pain, post-operative pain, visceral pains like chronic pelvic pain, cystitis, IBS, pancreatitis, sciatica, diabetic neuropathy, HIV neuropathy, asthma, cough, IBD, psoriasis, gastro-esophageal reflux disease (GERD), emesis, urinary incontinence and hyperactive bladder.

12. Use of the compound of formula I according to any one of claims 1 to 5, in the manufacture of a medicament for the treatment of VR1 mediated disorders and for the treatment of acute and chronic pain disorders and acute and chronic inflammatory pain.

13. A method of treatment of VR1 mediated disorders and for treatment of acute and chronic pain disorders and acute and chronic inflammatory pain, comprising administering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compound of formula I, according to any one of claims 1 to 5.

14. A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound of formula I, according to any one of claims 1 to 5, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.


15. The pharmaceutical formulation according to claim 14, for use in the treatment of VR1 mediated disorders and for treatment of acute and chronic pain disorders and acute and chronic inflammatory pain.

16. Use of compounds 4-tert-Butyl-N-(2-formyl-benzothiazol-5-yl)-benzamide and 5-(4-tert-butylbenzoylamino)benzothiazol-2-ylcarboxylic acid as intermediates in the preparation of the compound of formula I.

2003-05-05

ABSTRACT

The present invention relates to new compounds of formula I,



(I)

- 5 wherein R^1 to R^4 are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**